Synergy of gemcitabine and lidamycin associated with NF-κB downregulation in pancreatic carcinoma cells  被引量:4

Synergy of gemcitabine and lidamycin associated with NF-κB downregulation in pancreatic carcinoma cells

在线阅读下载全文

作  者:Jing CHEN Shu-ying WU Zhi-gang OU-YANG Yong-su ZHEN 

机构地区:[1]Istitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China [2]North China Coal Medical College, Tangshan 063000, China

出  处:《Acta Pharmacologica Sinica》2008年第5期614-619,共6页中国药理学报(英文版)

基  金:This work was supported by The National High Technology Research and Development Program of China (No 2004AA2Z3950) and a grant from the National Natural Science Foundation of China (No 30400597).

摘  要:Aim: To investigate the effects on human pancreatic cancer PANC- 1 and SW1990 cells using a combination of lidamycin (LDM) and gemcitabine. Methods: A 3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was used to determine the growth inhibition of drugs in PANC-1 and SW1990 cells. The effects on apoptosis were measured by terminal uridine deoxynucleotidyl transferase dUTP nick end labeling assay and flow cytometry combined with fluorescein-isothiocyanate-Annexin V/propidium iodide staining. The activity of caspase-3 was measured with a special assay kit. The mitochondrial membrane potential was determined by confocal microscopy analyses. The level of mRNA encoding K-ras in the cells was determined by RT-PCR analysis. The expression of K-ras, NF-κB, and Bcl-2 was detected by Western blotting analysis. Results: There was a significant reduction in proliferation in the pancreatic cancer cell lines treated with a combination of gemcitabine and LDM. The overall growth inhibition directly correlated with apoptotic cell death. LDM potentiated the gemcitabine-induced cell killing by reducing mitochondrial membrane potential and increasing the caspase-3 activity. Notably, the K-ras mRNA level was significantly reduced with the combination of gemcitabine and LDM. The results for K-ras, NF-rd3, and Bcl-2 proteins also showed downregulation in the combi- nation group relative to the single-agent treatment and the untreated control. Conclusion: LDM can potentiate the growth inhibition induced by gemcitabine in human pancreatic cancer cells, and the synergy may be associated with NF-κB downregulation.Aim: To investigate the effects on human pancreatic cancer PANC- 1 and SW1990 cells using a combination of lidamycin (LDM) and gemcitabine. Methods: A 3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was used to determine the growth inhibition of drugs in PANC-1 and SW1990 cells. The effects on apoptosis were measured by terminal uridine deoxynucleotidyl transferase dUTP nick end labeling assay and flow cytometry combined with fluorescein-isothiocyanate-Annexin V/propidium iodide staining. The activity of caspase-3 was measured with a special assay kit. The mitochondrial membrane potential was determined by confocal microscopy analyses. The level of mRNA encoding K-ras in the cells was determined by RT-PCR analysis. The expression of K-ras, NF-κB, and Bcl-2 was detected by Western blotting analysis. Results: There was a significant reduction in proliferation in the pancreatic cancer cell lines treated with a combination of gemcitabine and LDM. The overall growth inhibition directly correlated with apoptotic cell death. LDM potentiated the gemcitabine-induced cell killing by reducing mitochondrial membrane potential and increasing the caspase-3 activity. Notably, the K-ras mRNA level was significantly reduced with the combination of gemcitabine and LDM. The results for K-ras, NF-rd3, and Bcl-2 proteins also showed downregulation in the combi- nation group relative to the single-agent treatment and the untreated control. Conclusion: LDM can potentiate the growth inhibition induced by gemcitabine in human pancreatic cancer cells, and the synergy may be associated with NF-κB downregulation.

关 键 词:LIDAMYCIN GEMCITABINE pancreatic cancer K-RAS NF-ΚB drug therapy  combination 

分 类 号:R735.9[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象